Plus therapeutics regains compliance with applicable nasdaq listing criteria

Houston, aug. 26, 2025 (globe newswire) -- plus therapeutics, inc. (nasdaq: pstv) (the “company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (cns) cancers, today announced that it received a letter (the “letter”) from nasdaq on august 22, 2025, confirming its compliance with nasdaq listing rule 5550(b). specifically, the letter confirms that the company is in compliance with both (1) the market value of listing securities (“mvls”) standard under 5550(b)(2), which requires certain companies to maintain a market value of listed securities of at least $35 million (the “mvls standard”), as well as compliance with (2) the alternative stockholders' equity threshold under 5550(b)(1), which requires certain companies to maintain stockholders' equity of at least $2.5 million (the “equity standard”).
PSTV Ratings Summary
PSTV Quant Ranking